[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Harmony Biosciences Holdings Inc (HRMY)

Harmony Biosciences Holdings Inc (HRMY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,784,841
  • Shares Outstanding, K 57,893
  • Annual Sales, $ 868,450 K
  • Annual Income, $ 158,690 K
  • EBIT $ 190 M
  • EBITDA $ 214 M
  • 60-Month Beta 0.97
  • Price/Sales 2.01
  • Price/Cash Flow 9.48
  • Price/Book 1.92

Options Overview Details

View History
  • Implied Volatility 60.61% (+1.76%)
  • Historical Volatility 35.98%
  • IV Percentile 51%
  • IV Rank 28.22%
  • IV High 127.87% on 09/15/25
  • IV Low 34.16% on 12/17/25
  • Expected Move (DTE 1) 2.45 (7.96%)
  • Put/Call Vol Ratio 0.17
  • Today's Volume 41
  • Volume Avg (30-Day) 98
  • Put/Call OI Ratio 0.95
  • Today's Open Interest 4,143
  • Open Int (30-Day) 4,879
  • Expected Range 28.31 to 33.21

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $0.93
  • Number of Estimates 3
  • High Estimate $0.94
  • Low Estimate $0.92
  • Prior Year $0.68
  • Growth Rate Est. (year over year) +36.76%

Price Performance

See More
Period Period Low Period High Performance
1-Month
28.74 +7.03%
on 04/20/26
34.99 -12.09%
on 04/21/26
+1.47 (+5.02%)
since 04/14/26
3-Month
25.90 +18.76%
on 02/24/26
37.59 -18.17%
on 02/17/26
-5.25 (-14.58%)
since 02/13/26
52-Week
25.52 +20.53%
on 10/20/25
40.87 -24.74%
on 12/15/25
-2.63 (-7.88%)
since 05/14/25

Most Recent Stories

More News
Harmony Biosciences Q1 Earnings Call Highlights

Harmony Biosciences (NASDAQ:HRMY) reported first-quarter 2026 net product revenue of $215.4 million, a 17% increase from $184.7 million in the prior-year quarter, as the company highlighted continued demand...

HRMY : 30.76 (-0.23%)
Harmony Biosciences Reports Q1 Financial Results and Confirms 2026 Net Revenue Guidance of Over $1 Billion; Reinforces 2026 Strategic Priorities

WAKIX® Net Revenue Grew 17% to $215.4 Million for First Quarter 2026; On Track for Full Year 2026 Net Revenues over $1 Billion Continue to Vigorously Protect WAKIX IP...

HRMY : 30.76 (-0.23%)
Will Harmony Biosciences Finally Address What Happens After Wakix Patent Expiration?

Barchart Research What to Expect from HRMY Earnings HRMY Generated May 6, 2026 Current Price $32.78 EPS Estimate $$0.76 Consensus Rating Moderate Buy Average Move 6.80% Will Harmony Biosciences Finally...

HRMY : 30.76 (-0.23%)
Harmony Biosciences to Report First Quarter 2026 Financial Results on May 7, 2026

Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report first quarter 2026 financial results on Thursday, May 7, 2026, before the open of the U.S. financial markets. Harmony...

HRMY : 30.76 (-0.23%)
Harmony Biosciences to Present Open-Label Extension Data From Phase 3 ARGUS Trial at the 2026 American Academy of Neurology Annual Meeting

Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will present encore open-label extension data from the company’s investigation of EPX-100 (clemizole hydrochloride) in the ongoing...

HRMY : 30.76 (-0.23%)
Harmony Biosciences Appoints Glenn Reicin as Chief Financial Officer

COMPANY REITERATES ITS 2026 NET REVENUE GUIDANCE OF OVER $1 BILLION IN WAKIX SALES

HRMY : 30.76 (-0.23%)
Harmony Biosciences Strengthens Executive Team With New Appointment and Announces Additions to Its Board

Appointments support Harmony’s next phase of growth and long‑term value creation

HRMY : 30.76 (-0.23%)
Harmony Biosciences to Participate in 25th Annual Needham Virtual Healthcare Conference

Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that Harmony's management team will participate in a fireside chat at the upcoming 25 th Annual Needham Virtual Healthcare...

HRMY : 30.76 (-0.23%)
Harmony Biosciences to Participate in Upcoming Investor Conferences

Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will attend the following upcoming investor conferences. Leerink Partners Global Healthcare Conference...

HRMY : 30.76 (-0.23%)
Harmony Biosciences Reports Strong 2025 Financial Results and Reiterates 2026 Net Revenue Guidance of Over $1 Billion

WAKIX 2025 Net Revenue of $868.5 Million; 2026 WAKIX Net Revenue Guidance of $1.0 – $1.04 Billion on Track for Blockbuster Status in Narcolepsy Recently Completed Settlements...

HRMY : 30.76 (-0.23%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Harmony Biosciences Holdings Inc.is a pharmaceutical company. It engages in developing and commercializing therapies for rare neurological disorders. Harmony Biosciences Holdings Inc.is based in Plymouth Meeting, Pennsylvania.

See More

Key Turning Points

3rd Resistance Point 31.97
2nd Resistance Point 31.69
1st Resistance Point 31.22
Last Price 30.76
1st Support Level 30.47
2nd Support Level 30.19
3rd Support Level 29.72

See More

52-Week High 40.87
Fibonacci 61.8% 35.01
Fibonacci 50% 33.19
Fibonacci 38.2% 31.38
Last Price 30.76
52-Week Low 25.52

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.